50th ICAAC Symposium: Comparing and Contrasting ARV Treatment Guidelines









About the Program

Program Overview

This one-hour live Internet symposium will compare and contrast the current DHHS, IAS-USA, and EACS Antiretroviral Treatment Guidelines and discuss the recent studies, including those presented at the 50th ICAAC, that may affect those guidelines. This program will feature 4 well-known and recognized thought leaders in the HIV field.

This program is certified for CME credit for US physicians by the Postgraduate Institute for Medicine.

Back to Top

Target Audience

This activity has been designed to meet the educational need of physicians involved in the care of patients with HIV infection.

Back to Top

Learning Objectives

After completing this activity, participants should be able to:

  • Explain the key similarities and differences of the DHHS, IAS-USA and EACS ARV Treatment Guidelines

  • Describe how best to apply ARV Treatment Guideline recommendations regarding the care of ARV-naïve and experienced patients

  • Analyze treatment options and construct appropriate ARV regimens based on each set of ARV Treatment Guidelines

Release Date:  September 21, 2010
Expiration Date: September 21, 2011

Estimated time to complete this Web symposium: 1 hour, 15 minutes

Media: Internet

Back to Top

Course Director and Moderator

Calvin J. Cohen, MD, MS
Research Director, CRI New England
Clinical Instructor, Harvard Medical School
Boston, Massachusetts


Paul Sax, MD
Member, DHHS Guidelines Panel
Clinical Director, Brigham and Women's
Division of Infectious Diseases and HIV Program
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Mauro Schechter, MD
Head, AIDS Research Laboratory,
Universidade Federal do Rio de Janeiro
Rio de Janeiro, Brazil

Anton Pozniak, MD
Chair, EACS Guidelines Panel
Consultant Physician Director of HIV Services
Department of HIV and Genitourinary Medicine
Chelsea and Westminster Hospital NHS Trust
London, United Kingdom

Back to Top  

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Postgraduate Institute for Medicine (PIM) and ViralEd, Inc.. PIM is accredited by the ACCME to provide continuing medical education for physicians.   

Back to Top

Credit Designation

Postgraduate Institute for Medicine designates this educational activity for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest

The Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The facultyreported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Dr. Calvin Cohen:

  • Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; ViiV
  • Consulting Fees: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec; Abbott
  • Speakers Bureau: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec

Dr. Anton Pozniak:

  • Consulting Fees: Merck; ViiV; Bristol-Myers Squibb; Boehringer Ingelheim; Roche; Gilead; Tibotec; Abbott
  • Speakers Bureau: Merck; ViiV; Bristol-Myers Squibb; Boehringer Ingelheim; Roche; Gilead; Tibotec; Abbott

Dr. Paul Sax:

  • Contracted Research: Gilead; Merck; Tibotec
  • Consulting Fees: Abbott; Bristol-Myers Squibb; Gilead; GlaxoSmithKline; Merck; Tibotec; ViiV

Dr. Mauro Schechter:

  • Contracted Research: Gilead; Bristol-Myers Squibb; Merck & Co.; Tibotec
  • Consulting Fees: Bristol-Myers Squibb; Merck & Co.; Abbott

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Jan Hixon, RN, BSN, MA; Trace Hutchison, PharmD; Julia Kimball, RN, BSN; Samantha Mattiucci, PharmD; Jan Schultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine (PIM), ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Instructions for Participation and Credit

There are no fees for participating and receiving credit for this activity.  During the period, September 21, 2010 through September 21, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; and 3) complete the post-test and evaluation form. 

To answer the questions, click on your selected choice for each answer then proceed to the next question.  We recommend that you print a copy of your answers before you submit them to us.  Once completed, click on the Submit Post-test at the bottom of the page.  Your post-test will automatically be graded.

If you successfully complete the post-test (score of 70% or higher). your certificate will be made available immediately.  Click on View Certificate and print the certificate for your records.  If you received a score of 69% or less, you will receive a message notifying you that you did not pass the post-test.  You may retake the post-test until successful.

You may complete the Post-test on-line at http://www.cmeuniversity.com/.

  • Click on "Find Post-Test/Evaluation by Course" on the navigation menu
  • Search by project ID 7491
  • Upon successfully completing the Post-test and Evaluation form, your certificate will be made available immediately.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Back to Top

Program Note: While there is mutual recognition of CME credits between Europe and the US, an application has been submitted to the European Union of Medical Specialists (UEMS) for approval to provide direct EACCME accredited continuing medical education for European participants.


 Supported by an educational grant from Merck & Co., Inc.

*This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings

Prepare to print

Share this page:

Get link code to this page     

Back to Top